ABSTRACT
Piperacillin–tazobactam (Zosyn, Tazocin) is a beta-lactam/beta-lactamase inhibitor combination first licensed in 1993. The combination is formulated as a sodium salt in an 8:1 piperacillin/tazobactam ratio. The Wyeth formulation has been reformulated to include ethylenediaminetetraacetic acid (EDTA) and sodium citrate, which permits simultaneous infusion with two aminoglycosides, gentamicin and amikacin, but not tobramycin (Wyeth, 2006).
